The following was posted on the Malecare Advanced Prostate Cancer Health Unlocked online support group. I have received permission to reprint it here because it might be helpful to some of you. FYI- Provenge is a cancer vaccine that helps to mobilize your own immune system to your prostate cancer. It is currently only [...]
Provenge, despite its demonstrated survival advantage, continues to be knocked as a viable treatment for men with castrate-resistant prostate cancer. What is Provenge? Provenge is immunotherapy for men with metastatic castrate-resistant prostate cancer. In other words, Provenge might help men live longer after their cancer has spread outside of the prostate and are no [...]
Despite its approval five years ago sipuleucel-T (Provenge) remains one of the most controversial treatments available for men with castrate resistant metastatic prostate cancer (mCRPC). Provenge has its advocates (Full Disclosure- I am) and it has many detractors. The detractors argue that it doesn’t work and they hang their hat on the argument that it [...]
It was announced today that preliminary results from the Phase II STAND trial demonstrates continued and what is described as a robust immune response with Provenge (sipuleucel-T) that continues two years after completing treatment in men with biochemically-recurrent prostate cancer (BRPC). This finding, along with data from the ongoing Phase IV registry PROCEED trial, are [...]
Dendreon, the manufacture of the only FDA approved immunologic therapy for prostate cancer had been burdened with significant debt. The debt came from their R&D of Provenge, their seeking FDA approval and the construction of three manufacturing plants to produce the treatment. Sadly, the company was unable to get its income ahead of its debt [...]